Using sulindac and new drug derivatives to treat cancer
Exploiting the immunomodulatory effects of sulindac and novel non-COX inhibitory derivatives for cancer treatment
This study is looking at how a medication called sulindac and its new versions might help fight cancer by targeting different ways that tumors grow, which could lead to safer treatment options for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Augusta University NIH-funded |
| Lab location | 1 site (Augusta, United States) |
| Project ID | NIH-10798236 on NIH RePORTER |
What this research studies
This research investigates the potential of sulindac and its novel derivatives to treat cancer by targeting specific enzymes involved in tumor growth, rather than the traditional cyclooxygenase pathway. The study aims to understand how these drugs can inhibit tumor cell growth and enhance the immune response against cancer cells. Patients may benefit from new treatment options that are less toxic than current NSAIDs, as the research focuses on non-COX-inhibitory mechanisms. The approach includes both laboratory studies and potential future clinical applications.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with certain types of cancer who may benefit from new therapeutic options.
Not a fit: Patients who are not diagnosed with cancer or those who have already exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective cancer treatments with fewer side effects.
How similar studies have performed: Other research has shown promise in using non-COX-inhibitory pathways for cancer treatment, indicating that this approach may be viable.
Where this research is happening
Augusta, United States
- Augusta University — Augusta, United States (Active)
Researchers
- Principal investigator: Zhou, Gang — Augusta University
- Study coordinator: Zhou, Gang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.